Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24539806 | 0.95 | TDP1 (0.36) | TDP1L3MBTL1BACE1 | |
| SCHEMBL24539818 | 0.94 | TDP1 (0.34) | TDP1L3MBTL1ABCG2CYP1A1CYP1A2 | |
| SCHEMBL24539814 | 0.94 | TDP1 (0.34) | TDP1L3MBTL1ABCG2CYP1A1CYP1A2 | |
| SCHEMBL27011993 | 0.93 | TDP1 (0.33) | TDP1L3MBTL1ABCG2CYP1A1CYP1A2 | |
| SCHEMBL24540014 | 0.93 | TDP1 (0.33) | TDP1L3MBTL1ABCG2CYP1A1CYP1A2 | |
| SCHEMBL24539810 | 0.93 | TDP1 (0.35) | TDP1L3MBTL1BACE1 | |
| SCHEMBL24539941 | 0.92 | PLA2G2A (0.35) | TDP1L3MBTL1ABCG2CYP1A1CYP1A2 | |
| SCHEMBL24539728 | 0.91 | CYP1A1 (0.32) | TDP1L3MBTL1ABCG2CYP1A1CYP1A2 | |
| SCHEMBL24539811 | 0.91 | CDC14B (0.32) | BACE1CRHR1 | |
| SCHEMBL27011775 | 0.91 | PLA2G2A (0.33) | BACE1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240023432-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | LT MATERIALS CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240023432-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | LT MATERIALS CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| WO-2022131546-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | 엘티소재주식회사 | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240023432-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | CYP1B1, NOTUM, CYP4F11 | TDP1 1330/4885L3MBTL1 1277/4885ABCG2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.